Instylla – Developing Next-generation Liquid Embolics
Instylla is a privately held company based in Bedford, MA, focused on developing next-generation liquid embolics for interventional radiology, with initial clinical applications in interventional oncology and peripheral hemostasis. The company’s first product, Embrace™ Hydrogel Embolic System, is designed for controlled, complete, and persistent embolization in these clinical conditions.
Instylla was founded in 2017 by Incept LLC and is funded by several leading venture capital groups.
Restoring life, hope, and joy to the world’s sickest patients by materializing novel embolization solutions to improve outcomes.
Amarpreet Sawhney, Ph.D., is the Founder, Chief Executive Officer and Chairman of the Board of Directors. He is also the CEO of Pramand LLC, and Rejoni, Inc. Prior to this Dr. Sawhney served as CEO and Chairman of Augmenix (acquired by Boston Scientific) and Ocular Therapeutix (NASDAQ: OCUL) . In addition, he is a general partner of Incept, LLC, an intellectual property holding company. Previously, Dr. Sawhney founded Confluent Surgical and served as its President and CEO prior to its acquisition by Covidien plc. He also was a technology founder of Focal, Inc., a biopharmaceutical company acquired by Genzyme Corporation, and a founder of AccessClosure, Inc., acquired by Cardinal Health. Dr. Sawhney’s innovations are the subject of over 120 issued and pending patents. He holds M.S. and Ph.D. degrees in chemical engineering from the University of Texas at Austin, as well as a B.Tech. in chemical engineering from the Indian Institute of Technology, Delhi India.
With a concentration in interventional radiology and oncology, Ray Lareau has over 25 years of experience in developing and commercializing innovative medical devices. Prior to joining Instylla in 2017, he was President and COO of High Performance Medical Solutions, a division of Hitachi America. He has also held positions of increasing responsibility in both operations and product development at Boston Scientific, Navilyst Medical, AngioDynamics, and Vortex Medical. Ray has over 30 issued and pending patents spanning short-term and implantable technologies. He holds a B.S. and M.S. in Plastics Engineering.
Amita Shah has over 28 years of experience in regulatory and quality for cardiovascular, neurological and implantable medical devices. She has worked for ConforMIS, Confluent Surgical, Hemasure, and CR Bard Vascular/Cardiology where she authored and successfully cleared more than 25 510ks and participated in the PMA approval process. Amita has an M.S. in Chemistry.
Ben Bell has over 20 years of experience in product design, development, commercialization, and manufacturing of medical devices. He has worked for Boston Scientific, Navilyst Medical, Angiodynamics, and Hitachi where he was responsible for the development and commercialization of medical devices in fields including Vascular Access, Peripheral Vascular, Endoscopy, and Cardiology. Ben holds a B.S. in Plastics Engineering. He also has over 20 issued and pending patents.
Janet has over 25 years of experience in a broad range of operational roles, including procurement, HR, accounting, and facilities build out and management at early-stage life science and technology companies and venture capital firms. She has held previous positions at Focal Inc, Charles River Ventures, Reva Systems, mValent, Prism Venture Partners, FirstFuel Software and Coretelligent.
Lynn Morrison has over 30 years of experience in clinical affairs for cardiovascular medical devices. She has worked in the cardiac catheterization laboratory as a licensed Cardiovascular Technologist, and for the medical device companies of ACS/Guidant, Avantec Vascular and Elixir Medical, designing and executing clinical studies enrolling more than 4000 patients worldwide. Lynn has a Masters in Public Health (MPH).